Replimune
REPL
19.07
-0.16
-0.83%
Replimune
US · REPL
#3130 by market cap
Listed 2018
19.07
-0.16
-0.83%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
About Replimune
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
- Founded
- 2017
- CEO
- Dr. Sushil Patel, PhD
- Employees
- 465
- Headquarters
- Woburn, Massachusetts, United States of America
- Fiscal year end
- 03-31
- Website
- replimune.com
Company profile
- Exchange
- US
- Symbol
- REPL
- Market-cap rank
- #3130
- Listing date
- 2018-07-20
- Market cap
- 1.81B
- Float cap
- 1.25B
- Shares out
- 94.80M
- Float shares
- 65.56M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.
Replimune discussion 0 comments